Ignite Creation Date:
2024-05-06 @ 12:29 PM
Last Modification Date:
2024-10-26 @ 1:00 PM
Study NCT ID:
NCT03778346
Status:
UNKNOWN
Last Update Posted:
2020-11-18
First Post:
2018-12-14
Brief Title:
Integrin β7 BCMA CS1 CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells
Sponsor:
The Sixth Affiliated Hospital of Wenzhou Medical University
Organization:
The Sixth Affiliated Hospital of Wenzhou Medical University
Study Overview
Official Title:
Integrin β7 BCMA CS1 CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells
Status:
UNKNOWN
Status Verified Date:
2020-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
According to the high expression of tumor cell-associated antigen CD138 integrin β7 CS1 CD38 and BCMA in patients with refractoryrecurrent multiple myeloma the fourth generation of CAR-T cellssimultaneously expressing IL7 and CCL19 with 10 different dual target combinations are used to minimize the tumor burden in the patient individually and precisely and improve the immunosuppressive microenvironment of the tumor thereby effectively treating refractoryrecurrent multiple myeloma
Detailed Description:
Multiple myelomaMM is one of the most common malignant diseases in the blood systemThere is still no cure for the disease which only control the development of the disease in various ways including proteasome inhibitors and immune regulator and hematopoietic stem cell transplantation Combined with the advantages of multiple therapies chimeric antigen receptor T cells CAR-T have gradually becoming one of the strongest and most powerful weapons against multiple myelomaThe basic principle is to use the patients own immune cells to clear cancer cells
MM is genetically and phenotypically heterogeneousAntigen escape and relapse after CAR-T treatment is a global problem so the effective treatment of refractoryrelapsing multiple myeloma with CAR-T cells usually requires targeting multiple antigens The investigators use Integrin β7a large family of molecules that are central regulators in multicellular biology and orchestrating cell-cell and cell-extracellular matrix ECM adhesive interactions from embryonic development to mature tissue function BCMAhighly expressed on malignant MM plasma cells and providing a substantial antiapoptotic signal making it an encouraging target for BCMA-directed immunotherapyCS1encoded by the SLAMF7 genea robust marker of normal plasma cells and malignant plasmaCD38encoded by the CD38 gene and functioning in cell adhesion signal transduction and calcium signaling and CD138known as syndecan 1 a surface protein expressed on most healthy and malignant plasma cells as an adhesion protein binding collagen and fibronectin molecules located in the extracellular matrix as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells thereby effectively treating refractoryrecurrent multiple myeloma
MM is genetically and phenotypically heterogeneousAntigen escape and relapse after CAR-T treatment is a global problem so the effective treatment of refractoryrelapsing multiple myeloma with CAR-T cells usually requires targeting multiple antigens The investigators use Integrin β7a large family of molecules that are central regulators in multicellular biology and orchestrating cell-cell and cell-extracellular matrix ECM adhesive interactions from embryonic development to mature tissue function BCMAhighly expressed on malignant MM plasma cells and providing a substantial antiapoptotic signal making it an encouraging target for BCMA-directed immunotherapyCS1encoded by the SLAMF7 genea robust marker of normal plasma cells and malignant plasmaCD38encoded by the CD38 gene and functioning in cell adhesion signal transduction and calcium signaling and CD138known as syndecan 1 a surface protein expressed on most healthy and malignant plasma cells as an adhesion protein binding collagen and fibronectin molecules located in the extracellular matrix as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells thereby effectively treating refractoryrecurrent multiple myeloma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None